Strides Pharma Science Limited (BOM:532531)
India · Delayed Price · Currency is INR | Market Cap | 88.26B +10.1% |
| Revenue (ttm) | 50.04B +8.1% |
| Net Income | 6.13B +79.6% |
| EPS | 66.55 +79.4% |
| Shares Out | n/a |
| PE Ratio | 14.39 |
| Forward PE | 12.79 |
| Dividend | 5.00 (0.53%) |
| Ex-Dividend Date | Jul 31, 2026 |
| Volume | 396,921 |
| Open | 989.90 |
| Previous Close | 957.00 |
| Day's Range | 970.05 - 1,055.90 |
| 52-Week Range | 769.60 - 1,231.45 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 1,338.67 (+34.94%) |
| Earnings Date | Jul 31, 2026 |
About Strides Pharma Science
Strides Pharma Science Limited, a pharmaceutical company, engages in the development, manufacturing, and marketing of pharmaceutical products in North America, Australia, Africa, Europe, India, the rest of Asia, and internationally. The company offers generic finished dosage formulations in a range of dosages, such as tablets, hard capsules, sachets, liquids, nasal sprays, topical formulations, and controlled substances; and therapeutic products, including antivirals, antibiotics, NSAIDs, and allergy treatment. It also provides branded generics... [Read more]
Financial Performance
In fiscal year 2026, Strides Pharma Science's revenue was 48.59 billion, an increase of 6.43% compared to the previous year's 45.65 billion. Earnings were 5.56 billion, a decrease of -84.52%.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for 532531 stock is "Strong Buy." The 12-month stock price target is ₹1,339, which is an increase of 34.94% from the latest price.
News
Strides Pharma Science Transcript: Q1 26/27
Q1 FY 2027 delivered 13% year-on-year revenue growth, with ex-U.S. markets up 17% and stable U.S. performance despite ongoing geopolitical and cost headwinds. Gross margins expanded to 60.9%, and PAT rose 57% year-on-year, aided by a one-time divestment gain.
Strides Pharma Science Quarterly report: Q1 2027
Strides Pharma Science has published its Q1 2027 quarterly earnings report on July 31, 2026.
Strides Pharma Science Slides: Q1 2027
Strides Pharma Science has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 31, 2026.
Strides partners with Ascent Capital valuing Pivot Path at ₹2,300 million
Strides Pharma Science Limited has announced a strategic investment by a consortium led by Ascent Capital in its subsidiary, Pivot Path Private Limited. The transaction values Pivot Path at approximat...
Strides Pharma Science Transcript: Q4 25/26
FY 2026 saw record EBITDA and PAT, driven by ex-U.S. market growth and margin expansion. U.S. business faced headwinds from a weak flu season and competition, but new launches and controlled substances are expected to drive growth from H2 FY 2027.
Strides Pharma Science Quarterly report: Q4 2026
Strides Pharma Science has published its Q4 2026 quarterly earnings report on May 18, 2026.
Strides Pharma Science Slides: Q4 2026
Strides Pharma Science has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 18, 2026.
Strides Pharma Science Annual report: Q4 2026
Strides Pharma Science has published its Q4 2026 annual report on May 18, 2026.
Pharma stocks surge today, April 23: Dr. Reddy's Lab gains 6.43%, Strides Pharma rises 5.01%, Orchid Pharma surges 5.77%
Shares of pharmaceutical sector companies traded broadly higher on April 23, 2026, with Dr. Reddy's Laboratories, Strides Pharma Science, Orchid Pharma, and Glenmark Pharma among the standout gainers,...
Strides Pharma shares over 3% after acquiring generic brands from Sandoz for US$ 12 million
Strides Pharma Science shares gained over 3% after the company announced a strategic acquisition aimed at expanding its footprint in the Sub-Saharan Africa (SSA) region. As of 9:38 AM, the…
Strides Pharma Science acquires generic brands from Sandoz for US$ 12 million
Strides Pharma Science Limited has announced a strategic acquisition to bolster its presence in the Sub-Saharan Africa (SSA) region. The company, through its step-down subsidiary Strides Pharma Intern...
Strides Pharma Science Transcript: Q3 25/26
Gross margins and profitability improved, with EBITDA and PAT showing strong year-on-year growth. Ex-U.S. markets drove revenue expansion, while U.S. business remained flat due to seasonal and competitive factors. Balance sheet metrics and operational cash flow strengthened.
Strides Pharma Science Quarterly report: Q3 2026
Strides Pharma Science has published its Q3 2026 quarterly earnings report on January 30, 2026.
Strides Pharma Science Slides: Q3 2026
Strides Pharma Science has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 30, 2026.
Strides Pharma Science shares jump over 4% after Q3 profit surges 130% YoY to Rs 202 crore
Shares of Strides Pharma Science climbed more than 4% on the NSE on Thursday, reacting positively to the company’s strong...
Strides Pharma Q3 Results: Net profit surges 130% YoY to Rs 202 crore, revenue up 3.6%
Strides Pharma Science reported a strong set of financial results for the third quarter, delivering sharp growth in profitability and...
Strides Pharma Science Transcript: Q2 25/26
Q2 and H1 FY26 delivered strong growth in revenue, margins, and profitability, driven by disciplined execution, operating leverage, and a focus on sustainable, long-term growth. U.S. and other regulated markets showed steady performance, with robust cash flow and debt reduction.
Strides Pharma Science Quarterly report: Q2 2026
Strides Pharma Science has published its Q2 2026 quarterly earnings report on October 31, 2025.
Strides Pharma Science Slides: Q2 2026
Strides Pharma Science has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on October 31, 2025.
Strides Pharma Science Transcript: Q1 25/26
Strong quarterly results with revenue of INR 11.2 billion, 19.5% EBITDA margin, and 81% EPS growth year-on-year. U.S. and growth markets performed well, while access markets faced funding challenges. Long-term U.S. sales guidance of $400 million by FY2028 remains intact.
Strides Pharma Science Quarterly report: Q1 2026
Strides Pharma Science has published its Q1 2026 quarterly earnings report on July 29, 2025.
Strides Pharma Science Slides: Q1 2026
Strides Pharma Science has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on July 29, 2025.
Strides Pharma shares hit 52-week high, jumps 3% after Q1 PAT jumps 81% YoY
Shares of Strides Pharma Science Ltd surged over 3% on July 29, hitting a fresh 52-week high of ₹968 on the NSE after the company reported robust Q1FY26 earnings. The stock was last seen trading at ₹9...
Strides Pharma Q1 Results: Revenue rises 6.2% YoY to Rs 1119 crore, Net Profit at Rs 105.6 crore
Strides Pharma Science Ltd reported a strong performance for the quarter ended June 30, 2025, with revenue from operations rising 6.2% YoY to ₹1119.7 crore. The company’s operational profit after tax ...
Strides Pharma Science Transcript: Q4 24/25
FY25 delivered strong revenue and EBITDA growth, surpassing guidance across all key metrics, with the US business leading at 22% growth. The company achieved significant deleveraging, maintained high margins, and is increasing R&D investment for future growth, targeting sustained high-teens EBITDA margins.